drugset / Trial / NCT03265444
Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of conducting phase 1 trial is to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells(CS10BR05) in subjects with Multiple System Atrophy. Evaluation of DLT by carotid artery(intra-arterial) injection according to dose-escalating in Multiple System Atrophy.
Timeline
- Start
- 2018-04-13
- Primary completion
- 2019-12-05
- Completion
- 2019-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS10BR05 | Cell therapy | 300000 cells/kg | Other |
| Subject | CS10BR05 | Cell therapy | 600000 cells/kg | Other |
| Subject | CS10BR05 | Cell therapy | 900000 cells/kg | Other |